MedTrace Logo

PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I

NCT04903665 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 495

Last updated 2022-07-28

No results posted yet for this study

Summary

This study is a prospective study aimed to develop and validate the performance of combined multi-omitcs assays for early detection of gynecologic cancers. Biomarkers of cfDNA methylation, ctDNA mutation and blood miRNA markers will be evaluated. The study will enroll approximately 495 female participants, including participants with gynecologic cancers or benign diseases.

Conditions

  • Gynecologic Cancer

Interventions

DEVICE

Multi-cancer early detection test

Blood collection and multi-cancer early detection testing

Sponsors & Collaborators

  • Guangzhou Burning Rock Bioengineering Ltd.

    collaborator INDUSTRY

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaohua Wu, M.D.&Ph.D · Department of Gynecological Oncology, Fudan University Shanghai Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-11
Primary Completion
2022-08-22
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04903665 on ClinicalTrials.gov